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Pulmonary arterial hypertension is a fatal disease with an
estimated survival rate of only 50% after 5 years [1]. Over
the last years, knowledge in the field of pulmonary
hypertension has grown consistently and significantly.
New diagnostic tools, as well as the efficacy of new
medications and drug combinations, have been described.
How to define and diagnose pulmonary arterial hypertension
is the first important issue. Should echocardiography be the
method of choice? It is easy to access, cheap and noninvasive.
However, the cut-off values are debatable. In the ESC guide-
lines of 2009 [2] an estimated peak pulmonary artery pressure
of >50 mmHg is stated as ‘pulmonary hypertension is likely’,
while a PAP of 37–50 is defined as ‘possible PH’. However, the
gold standard remains heart catheterisation. Now the definition
is made using amean pulmonary artery pressure of 25 mmHg
or more. Age and gender seem to have an important impact on
the incidence and severity of PH. For instance, female patients
with an atrial septal defect do present with pulmonary
hypertension, while in male ASD patients pulmonary hyper-
tension is seldom if ever seen.
In order to simplify the clinical management of
patients, the classification of pulmonary hypertension
was changed in 2009 [3]. Pre-capillary PH is defined as a
wedge pressure <15mmHg and can be divided into pulmonary
arterial hypertension, PH due to lung disease, chronic
thromboembolic PH or PH with unclear and/or multifactorial
mechanisms. Post-capillary PH is defined as a wedge pressure
above 15 mmHg and is due to left-sided heart disease.
Who should be screened for pulmonary hypertension?
Should all patients undergoing non-cardiac surgery by
tested? Echocardiography and certainly heart catheterisa-
tion are not routinely performed, but when complications
arise postoperatively, pulmonary hypertension is not
seldom detected and although the underlying cause may
vary, the prognosis is unfavourable. One could argue that
echocardiography screening preoperatively in patients
over the age of 60 years may detect high-risk patients
for general surgery. Patients known with pulmonary
hypertension should be counselled against surgery, or if
it is decided to proceed with surgery a team of surgeons,
anaesthetists, intensivists and others should make a
treatment plan for optimal perioperative care.
Advances in treatment of pulmonary arterial hyperten-
sion over the past 15 to 20 years have dramatically reduced
the morbidity and mortality of the disease. A reduction of
43% in mortality and 61% in hospitalisations was found in
a recent meta-analysis [4]. However the current medication
is expensive and has major drawbacks so it is very
important to treat the patients who might benefit. At the
moment there are probably many patients left untreated
who could benefit, for instance adult patients with PH
associated with congenital heart disease. There is also an
interesting group of patients with primary left-sided heart
disease who have disproportionately high pulmonary
pressures. In patients who have undergone a successful
procedure for aortic or mitral stenosis the pulmonary
arterial pressures may remain elevated, although the wedge
pressure has normalised. The indication to treat these
patients with disproportionately high pulmonary pressures
remains controversial. For patients with left-sided systolic
dysfunction with secondary pulmonary hypertension, no
benefit of treatment was found and in fact may have a
negative effect on outcome, but for the patients with
disproportionately high pulmonary hypertension no studies
are available as yet.
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We hope you enjoy reading this focus issue of the
Netherlands Heart Journal, dedicated to several aspects of
the rapidly evolving field of Pulmonary Hypertension [5–9].
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